Akiva Felt

In a report published Friday, Oppenheimer analyst Akiva Felt initiated coverage on Amarin (NASDAQ: AMRN) with a Perform rating and $8.00 price target. In the report, Oppenheimer noted, “We are initiating coverage of AMRN with a Perform rating and $8 price target. Amarin's lead drug, Vascepa, is...

In a report published Friday, Oppenheimer analyst Akiva Felt initiated coverage on Intercept Pharmaceuticals (NASDAQ: ICPT) with an Outperform rating and $60.00 price target. In the report, Oppenheimer noted, “We are initiating coverage of Intercept (ICPT) with an Outperform rating and $60...

In a report published Friday, Oppenheimer analyst Akiva Felt assumed coverage on Medicines Company (NASDAQ: MDCO) with a Perform rating. In the report, Oppenheimer noted, “We are assuming coverage of The Medicines Company (MDCO) with a Perform rating as we believe current valuation levels...

In a report published Friday, Oppenheimer analyst Akiva Felt assumed coverage on Questcor Pharmaceuticals (NASDAQ: QCOR), upgraded the rating from Perform to Outperform, and a $57.00 price target. In the report, Oppenheimer noted, “We are assuming coverage of Questcor Pharmaceuticals and...